MiR-216b通过靶向ABCG1促进破骨细胞形成并减少胆固醇流出

目的 研究miR-216b在破骨细胞分化中的功能和靶基因,探讨其对破骨细胞胆固醇外流的影响.方法 建立RANKL刺激诱导RAW 264.7破骨细胞前体细胞分化的细胞模型.进行抗酒石酸酸性磷酸酶(TRAP)染色测定以评估破骨细胞分化.通过生物信息学分析和双荧光素酶报告基因预测和分析miR-216b与其靶基因ABCG13'...     

破骨细胞骨吸收功能的检测方法

破骨细胞是一种多核的,具有骨吸收功能的骨组织细胞,在骨吸收过程中起着至关重要的作用.破骨细胞骨吸收功能的异常会引发一系列的临床病症,如骨质疏松症、关节置换术后假体松动、骨硬化症和牙周病变等.破骨细胞骨吸收功能的进一步研究对于各类骨疾病的防治具有重要的意义.然而破骨细胞骨吸收功能的检测方法一直以来是制约破骨细胞研究的瓶颈之一.为此,围绕破骨细胞骨吸收功能的检测方法做一综述.     

人破骨细胞的原代培养和生物学特性

维持骨体积是骨吸收与骨形成相对平衡的结果,如失去这种稳定,则发生病理性变化,骨吸收破坏是主要现象之一,但关于骨吸收机理还不清楚。近些年来随着骨细胞培养技术的发展,使人们对骨吸收有了进一步认识,目前公认破骨细胞是骨吸收作用的主要承担者。为此,大多数学者从破骨细胞入手,对破骨细胞的结构和功能等进行研究。目前已从多种动物骨组织中分离出破骨细胞。本实验是通过建立人的破骨细胞分离、培养方法,为进一步开展骨吸收机理的研究奠定基础。     

小鼠破骨细胞诱导及成纤维生长因子受体表达检测

目的:检测成纤维生长因子受体(fibroblast growth factor receptors,FGFRs)在小鼠破骨细胞中的表达情况,为探讨FGFRs时破骨细胞的直接调控作用奠定基础.方法:采用巨噬细胞集落刺激因子(macrophage colony stimulating factor,M-CSF)和破骨细胞分化因子(receptor activator of nuclear factor-B ligand,RANKL)诱导小鼠骨髓单核细胞分化为破骨细胞.提取细胞总RNA后经逆转录获得小鼠破骨细胞cDNA,根据FGFRs基因编码区序列设计的引物进行PCR扩增并对PCR扩增产物进行测序.为进一步验证转录水平的结果,提取细胞总蛋白电泳后进行免疫印迹实验.结果:诱导5d后可见TRAP( )多核细胞出现,小鼠破骨细胞在转录水平和翻译水平均只可检测到FGFR1和FGFR3基因的表达产物.结论:M=CSF和RANKL可成功诱导出小鼠破骨细胞,FGFR1和FGFR3基因在小鼠破骨细胞中均有表达.     

环孢素A抑制骨水泥颗粒诱导破骨细胞形成及功能

目的:探讨环孢素A对颗粒诱导破骨细胞形成及功能的影响。方法:取SD仔鼠双侧股骨和胫骨的骨髓,以不含血清的α-MEM培养液洗涤并收集骨髓细胞,再将细胞重悬于含10%胎牛血清及10~(-8)mol/L1,25-(OH)_2D_3的α-MEM培养液中,细胞计数后配成1.5×10~7/ml的细胞悬液,加入聚甲基丙烯酸甲酯(PMMA)颗粒和不同浓度的环孢素A(10~((-8)mol/L、10~(-7)mol/L、10~(-6) mol/L)于24孔培养板进行培养,并设置阳性对照组(只加PMMA颗粒)和阴性对照组(PMMA颗粒和CsA均不加),每组均有4孔放置骨磨片1片进行培养。培养2周后,行抗酒石酸(TRAP)染色检测破骨细胞形成;骨磨片行甲苯胺蓝染色观察。结果:PM- MA颗粒能够诱导大量TRAP染色阳性的破骨细胞形成,骨磨片有吸收陷窝形成;用环孢素A(10~(-8)mol/L、10~(-7)mol/L)和PMMA颗粒共同培养下TRAP染色阳性的破骨细胞形成数量明显减少,环孢素A浓度达到10~(-6)mol/L时无TRAP染色阳性的破骨细胞形成;环孢素A浓度在(10~(-8)mol/L、10~(-7)mol/L)时骨磨片有吸收陷窝形成,但少于阳性对照组,在10~(-6)mol/L时骨磨片则无吸收陷窝的形成。结论:环孢素A对PMMA颗粒诱导的破骨细胞的形成有着明显的抑制作用,且呈剂量依赖性。     

培养破骨细胞扫描电镜样本制备方法的探讨

目的:探讨体外培养的破骨细胞在自制牛股骨磨片和细胞爬片中扫描电镜制备方法。方法:实验分两组,一组采用新鲜牛股骨制备成5mm×5mm大小的薄片,作为共培养之需;另一组,采用盖玻片制成5mm×5mm的细胞爬片。分别以5×104种植于骨磨片和爬片,培养5天后进行扫描电镜的制备并观察。结果:破骨细胞在牛骨磨片表面生长良好,充分伸展,有细胞突起伸入到实验组材料深部,并形成骨陷窝;在爬片表面生长的破骨细胞,细胞生长良好,粘附性强,细胞之间相互连接较紧密,细胞表面突起明显。结论:牛股骨磨片与破骨细胞在体外相容良好,材料有利于破骨细胞的生长及细胞功能的表达,而破骨细胞爬片更适于细胞外形的观察。将两种方法结合既能反映破骨细胞的形态结构又能展示其破骨功能。     

培养破骨细胞扫描电镜样本制备方法的探讨

目的：探讨体外培养的破骨细胞在自制牛股骨磨片和细胞爬片中扫描电镜制备方法。方法：实验分两组,一组采用新鲜牛股骨制备成5mm×5mm大小的薄片,作为共培养之需;另一组,采用盖玻片制成5mm×5mm的细胞爬片。分别以5×104种植于骨磨片和爬片,培养5天后进行扫描电镜的制备并观察。结果：破骨细胞在牛骨磨片表面生长良好,充分伸展,有细胞突起伸入到实验组材料深部,并形成骨陷窝;在爬片表面生长的破骨细胞,细胞生长良好,粘附性强,细胞之间相互连接较紧密,细胞表面突起明显。结论：牛股骨磨片与破骨细胞在体外相容良好,材料有利于破骨细胞的生长及细胞功能的表达,而破骨细胞爬片更适于细胞外形的观察。将两种方法结合既能反映破骨细胞的形态结构又能展示其破骨功能。     

小鼠核因子κB受体活化因子配基活性区的克隆、表达及生物活性分析

核因子κB受体活化因子配基是诱导破骨细胞分化、成熟的关键因子,在生物医学研究中应用广泛。本实验以小鼠的骨髓细胞cDNA为模板,采用PCR技术获得小鼠核因子κB受体活化因子配基活性区基因,并将该基因克隆至His标签的融合蛋白表达载体pET28a(+),经鉴定正确的质粒转化至BL21表达菌株中。通过调节诱导目的蛋白表达的培养温度、IPTG浓度及诱导时间,筛选出重组融合蛋白表达的最佳条件。将纯化后的重组蛋白稀释成不同浓度,刺激小鼠破骨前体细胞Raw264.7细胞分化,经抗酒石酸酸性磷酸酶染色后可见破骨细胞的形成,表明该重组蛋白具有较好的生物活性,可替代商品化的鼠源核因子κB受体活化因子配基。     

破骨细胞伪足小体的结构和功能

破骨细胞是一种由造血干细胞分化而来的具有骨吸收功能的多核细胞。破骨细胞的骨吸收功能与其肌动蛋白骨架的完整性有关。研究表明,破骨细胞肌动蛋白骨架的基本结构为伪足小体（podosome）。在破骨细胞分化的不同阶段,伪足小体呈现不同的形态结构。伪足小体的形成过程及结构完整性直接影响着破骨细胞的分化及其骨吸收活性。深入研究伪足小体的结构和功能可为探索破骨细胞的骨吸收机制和寻找骨骼疾病药物作用靶点提供新的思路。该文将围绕破骨细胞伪足小体的结构、功能及其调节机制进行综述。     

RANKL与骨重建

骨是一种动态更新的组织,它不断进行骨吸收（bone resorption）与骨形成（bone formation）的平衡,这个过程称之为骨重建（bone remodeling）．核因子κB受体活化因子配体（receptor activator of nuclear factor κB ligand,RANKL）是骨吸收和骨形成耦联的关键,具有诱导破骨细胞（osteoclast, OC）生成、活化,抑制破骨细胞凋亡的作用．RANKL最初发现于活化的T细胞,但骨重建过程中RANKL主要来源于骨细胞、成骨细胞和骨髓基质细胞．RANKL/核因子κB受体活化因子（receptor activator of nuclear factor κB,RANK）/骨保护素（osteoprotegerin, OPG）信号通路在成骨细胞调控破骨细胞生成的过程中起着重要的调节作用,是维持骨重建平衡的关键．本文就RANKL及其在骨中的分子作用机制作一综述.     

Substituted phenyl as a steroid A-ring mimetic: Providing agonist activity to a class of arylsulfonamide nonsteroidal glucocorticoid ligands

A class of arylsulfonamide glucocorticoid receptor agonists that contains a substituted phenyl group as a steroid A-ring mimetic is reported. The structural design and SAR that provide the functional switching of a GR antagonist to an agonist is described. A combination of specific hydrogen bonding and lipophilic elements on the A-ring moiety is required to achieve potent GR agonist activity. This study culminated in the identification of compound 23 as a potent GR agonist with selectivity over the PR and MR nuclear hormone receptors.     

The ecdysteroid receptor

Summary

The steroid molting hormone of insects and other arthropods regulates gene activity in target tissues through its association with a specific, high affinity receptor protein. In this review we summarize recent advances in several areas of ecdysteroid receptor research, including efforts to characterize and purify the receptor protein, cytochemical studies of its tissue distribution and subcellular localization during development, and current molecular genetic studies ecdysteroid action.     

雄激素和雌激素受体药物筛选方法的研究进展

雄激素和雌激素受体通过与相应激素特异性结合促进细胞分化和组织生长,发挥重要的生理功能,其功能失调可诱发多种疾病。雄激素和雌激素受体的选择性调节剂是治疗相关疾病的重要药物。基于基因组学、分子生物学、细胞生物学和生物信息学等最新研究成果而发展形成的实验技术或方法被用于新型雄激素和雌激素受体调节剂的筛选,显著加快了新药开发的进程。     

Analysis of 3D models of octopus estrogen receptor with estradiol: evidence for steric clashes that prevent estrogen binding

Relatives of the vertebrate estrogen receptor (ER) are found in Aplysia californica, Octopus vulgaris, Thais clavigera, and Marisa cornuarietis. Unlike vertebrate ERs, invertebrate ERs are constitutively active and do not bind estradiol. To investigate the molecular basis of the absence of estrogen binding, we constructed a 3D model of the putative steroid-binding domain on octopus ER. Our 3D model indicates that binding of estradiol to octopus ER is prevented by steric clashes between estradiol and amino acids in the steroid-binding pocket. In this respect, octopus ER resembles vertebrate estrogen-related receptors (ERR), which have a ligand-binding pocket that cannot accommodate estradiol. Like ERR, octopus ER also may have the activation function 2 domain (AF2) in a configuration that can bind to coactivators in the absence of estrogens, which would explain constitutive activity of octopus ER.     

降钙素基因相关肽家族受体及其受体活性修饰蛋白

降钙素基因相关肽家族是一类多功能的激素家族 ,参与人体的多种生物学功能 ,与多种疾病有关。降钙素基因相关肽受体包括降钙素受体 (CTR)和降钙素受体样受体 (CRLR) ,CTR可以独自与降钙素结合 ,而CRLR必须与一组称作受体活性修饰蛋白 (RAMPs)的蛋白质共同作用才能发挥生物学功能。综述CTR的研究概况及CRLR与RAMPs相互作用的机制和表达调控 ,以期为人们设计新型药物提供参考。     

新型抗抑郁药物分子靶标研究进展

抑郁症是一种严重的精神障碍疾病,其发病机制复杂。近年来随着对抑郁症发病机制的深入研究,发现了一些基于非单胺递质的 新型抗抑郁药物分子靶标。综述N -甲基-D-天冬氨酸（NMDA）受体、促肾上腺皮质激素释放因子（CRF）受体、阿片受体、γ-氨基丁 酸B(GABAB) 受体、乙酰胆碱受体等抗抑郁药物作用的新靶标及其相应分子机制研究进展,为开发高效、安全的抗抑郁症新药提供参考。     

Ago-Allosteric Modulation and Other Types of Allostery in Dimeric 7TM Receptors

Conventionally, an allosteric modulator is neutral in respect of efficacy and binds to a receptor site distant from the orthosteric site of the endogenous agonist. However, recently compounds being ago-allosteric modulators have been described i.e., compounds acting both as agonists on their own and as enhancers for the endogenous agonists in both increasing agonist potency and providing additive efficacy—superagonism. The additive efficacy can also be observed with agonists, which are neutral or even negative modulators of the potency of the endogenous ligand. Based on the prevailing dimeric concept for 7TM receptors, it is proposed that the ago-allosteric modulators bind in the orthosteric binding site, but–importantly–in the “other” or allosteric protomer of the dimer. Hereby, they can act both as additive co-agonists, and through intermolecular cooperative effects between the protomers, they may influence the potency of the endogenous agonist. It is of interest that at least some endogenous agonists can only occupy one protomer of a dimeric 7TM receptor complex at a time and thereby they leave the orthosteric binding site in the allosteric protomer free, potentially for binding of exogenous, allosteric modulators. If the allosteric modulator is an agonist, it is an ago-allosteric modulator; if it is neutral, it is a classical enhancer. Molecular mapping in hetero-dimeric class-C receptors, where the endogenous agonist clearly binds only in one protomer, supports the notion that allosteric modulators can act through binding in the “other” protomer. It is suggested that for the in vivo, clinical setting a positive ago-allosteric modulator should be the preferred agonist drug.     

Proteinase-activated receptors, nucleotide P2Y receptors, and μ-opioid receptor-1B are under the control of the type I transmembrane proteins p23 and p24A in post-Golgi trafficking

We recently characterized the proteinase-activated receptor (PAR)-2, a G protein-coupled receptor (GPCR), as the first cargo protein recognized by p24A. Here, we demonstrate that p24A binds to several other GPCRs, including PAR-1, the nucleotide receptors P2Y(1), P2Y(2), P2Y(4), and P2Y(11), as well as the μ-opioid receptor 1B. The acidic amino acid residues Glu and Asp at the second extracellular loop of GPCRs are essential for interaction with p24A. p23, another member of the p24 family, also interacts with GPCRs, similar to p24A. However, p23 shows a delayed dissociation from PAR-2 after activation of PAR-2, compared to the dissociation between PAR-2 and p24A. p24A and p23 arrest both P2Y(4) receptor and μ-opioid receptor 1B at the intracellular compartments, as observed for PAR-2. A comparable result was obtained when we studied primary rat astrocytes in culture. Over-expression of the N-terminal p24A fragment impairs PAR-2 resensitization in astrocytes that extends our findings to a native system. In summary, we demonstrate that p24A and p23 are specific cargo receptors of GPCRs and differentially control GPCR trafficking in the biosynthetic pathway, and thereby, p24A and p23 regulate GPCR signaling in astrocytes.     

The insulin-binding domain of insulin receptor is encoded by exon 2 and exon 3.

Insulin receptors are disulfide-linked oligotetramers composed of two heterodimers each containing a 130-kDa alpha subunit and a 90-kDa beta subunit. Insulin binds to the extracellular alpha subunit, and in the process stimulates the autophosphorylation of the beta subunit and the expression of tyrosine kinase activity. Studies combining the use of photoaffinity labeling and immunoprecipitation with anti-peptide antibody have directly demonstrated that the cysteine-rich domain, encoded by exon 3, in the alpha subunit is part of the insulin-binding site of the receptor. Experiments with chimeric insulin receptors and chimeric insulin-like growth factor I receptors have confirmed that the cysteine-rich domain constitutes a part of the insulin-binding site. In addition, results from these experiments suggest that the N-terminal sequence, encoded by exon 2, in the alpha subunit also participates in insulin binding. In this review it is proposed that, assuming two insulin-binding sites per each holoreceptor oligotetramer, each insulin-binding domain may contain respectively two sub-domains for hydrophobic and charge contact with insulin, and that high-affinity binding would require the interaction of both subunits with the possibility of each subunit reciprocally contributing one of the sub-domains.